BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 14709933)

  • 1. Relapse after high-dose therapy in relapsed Ewing's tumor patients: effects of maintenance chemotherapy in two selected patients?
    Laws HJ; van Kaick B; Pape H; Paulussen M; Göbel U
    Onkologie; 2003 Dec; 26(6):573-7. PubMed ID: 14709933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimodality diagnostics and megatherapy in poor prognosis Ewing's tumor patients. A single-center report.
    Laws HJ; Burdach S; van Kaick B; Engel B; Dirksen U; Körholz D; Pape H; Kahn T; Merck H; Schmitz M; Heyll A; Dockhorn-Dworniczak B; Jürgens H; Göbel U
    Strahlenther Onkol; 1999 Oct; 175(10):488-94. PubMed ID: 10554643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiotherapy and high-dose chemotherapy in advanced Ewing's tumors.
    Pape H; Laws HJ; Burdach S; van Kaik B; Glag M; Gripp S; Wittkamp M; Jürgens H; Göbel U; Schmitt G
    Strahlenther Onkol; 1999 Oct; 175(10):484-7. PubMed ID: 10554642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose chemotherapy and autologous peripheral blood stem-cell transfusion after conventional chemotherapy for patients with high-risk Ewing's tumors.
    Tanaka K; Matsunobu T; Sakamoto A; Matsuda S; Iwamoto Y
    J Orthop Sci; 2002; 7(4):477-82. PubMed ID: 12181663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [High-dosage chemotherapy in primary metastasized and relapsed Ewing's sarcoma. (EI)CESS].
    Fröhlich B; Ahrens S; Burdach S; Klingebiel T; Ladenstein R; Paulussen M; Zoubek A; Jürgens H
    Klin Padiatr; 1999; 211(4):284-90. PubMed ID: 10472563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial.
    Dunst J; Jürgens H; Sauer R; Pape H; Paulussen M; Winkelmann W; Rübe C
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):919-30. PubMed ID: 7607966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria.
    Burdach S; van Kaick B; Laws HJ; Ahrens S; Haase R; Körholz D; Pape H; Dunst J; Kahn T; Willers R; Engel B; Dirksen U; Kramm C; Nürnberger W; Heyll A; Ladenstein R; Gadner H; Jürgens H; Go el U
    Ann Oncol; 2000 Nov; 11(11):1451-62. PubMed ID: 11142486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
    Kushner BH; Meyers PA
    J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive combined modality therapy including low-dose TBI in high-risk Ewing's Sarcoma Patients.
    Kinsella TJ; Glaubiger D; Diesseroth A; Makuch R; Waller B; Pizzo P; Glatstein E
    Int J Radiat Oncol Biol Phys; 1983 Dec; 9(12):1955-60. PubMed ID: 9463099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the istituto rizzoli.
    Bacci G; Ferrari S; Bertoni F; Donati D; Bacchini P; Longhi A; Brach Del Prever A; Forni C; Rimondini S
    J Clin Oncol; 2000 Feb; 18(4):885-92. PubMed ID: 10673532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
    Kushner BH; Meyers PA; Gerald WL; Healey JH; La Quaglia MP; Boland P; Wollner N; Casper ES; Aledo A; Heller G
    J Clin Oncol; 1995 Nov; 13(11):2796-804. PubMed ID: 7595741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.
    Tural D; Molinas Mandel N; Dervisoglu S; Oner Dincbas F; Koca S; Colpan Oksuz D; Kantarci F; Turna H; Selcukbiricik F; Hiz M
    Jpn J Clin Oncol; 2012 May; 42(5):420-6. PubMed ID: 22416252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies.
    Bacci G; Picci P; Ferrari S; Mercuri M; Brach del Prever A; Rosito P; Barbieri E; Tienghi A; Forni C
    Cancer; 1998 Mar; 82(6):1174-83. PubMed ID: 9506366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours.
    McTiernan A; Driver D; Michelagnoli MP; Kilby AM; Whelan JS
    Ann Oncol; 2006 Aug; 17(8):1301-5. PubMed ID: 16782749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma.
    Burdach S; Jürgens H; Peters C; Nürnberger W; Mauz-Körholz C; Körholz D; Paulussen M; Pape H; Dilloo D; Koscielniak E
    J Clin Oncol; 1993 Aug; 11(8):1482-8. PubMed ID: 8101562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow.
    Thiel U; Wawer A; von Luettichau I; Bender HU; Blaeschke F; Grunewald TG; Steinborn M; Röper B; Bonig H; Klingebiel T; Bader P; Koscielniak E; Paulussen M; Dirksen U; Juergens H; Kolb HJ; Burdach SE
    Oncotarget; 2016 Oct; 7(43):70959-70968. PubMed ID: 27486822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone.
    Ataergin S; Ozet A; Solchaga L; Turan M; Beyzadeoglu M; Oysul K; Arpaci F; Komurcu S; Surenkok S; Ozturk M
    Med Oncol; 2009; 26(3):276-86. PubMed ID: 18989798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
    Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
    N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibility study.
    Czyzewski EA; Goldman S; Mundt AJ; Nachman J; Rubin C; Hallahan DE
    Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):569-77. PubMed ID: 10348286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis.
    Meyers PA; Krailo MD; Ladanyi M; Chan KW; Sailer SL; Dickman PS; Baker DL; Davis JH; Gerbing RB; Grovas A; Herzog CE; Lindsley KL; Liu-Mares W; Nachman JB; Sieger L; Wadman J; Gorlick RG
    J Clin Oncol; 2001 Jun; 19(11):2812-20. PubMed ID: 11387352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.